Lincocine

Quick links to important sections

Lincocine

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lincocine

Property Description
Active Ingredient Lincomycin
Form Sterile solution for injection
Pharmacological Class Lincosamide antibiotic
General Purpose To combat severe bacterial infections
Origin Natural product (from Streptomyces lincolnensis)

What Type of Medicine is Lincocine?

Lincocine is a specific pharmaceutical preparation containing the active ingredient Lincomycin, which is classified as an antibiotic agent belonging to the lincosamide class of antibacterials. This medicine is designed to halt the growth of susceptible bacteria. Lincomycin is considered a natural product because it is derived from the controlled fermentation processes of the bacterium Streptomyces lincolnensis. It possesses a distinct binding mechanism, making it a recognized option for specific bacterial susceptibilities.

Formulation and General Therapeutic Purpose

Lincocine is typically prepared as a sterile solution intended for parenteral administration—meaning it is administered by injection, either into a muscle (intramuscularly) or into a vein (intravenously). This injectable form positions Lincocine for use in more acute settings where immediate, systemic drug delivery is required. The drug's mechanism involves inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. This action helps stop the bacteria from growing and spreading. The general therapeutic purpose of Lincocine is to control and resolve bacterial infections caused by susceptible organisms. Lincomycin is a member of the lincosamide class for the treatment of certain infections.

Regulatory References

  1. WHO Essential Medicines List (eEML) Lincomycin Entry

What side effects are possible with Lincocine?

Possible Side Effects and Safety Information

Lincocine (Lincomycin) has an official safety profile categorized by frequency and the body system affected, as documented by regulatory authorities. The most frequently observed adverse reactions fall under Gastrointestinal Disorders and reactions at the injection site.


Frequency Classification and System-Organ Classes

The following categories reflect the officially documented occurrence of adverse reactions:

  • Common (affecting 1 to 10 users in 100): Gastrointestinal effects, including Diarrhea, Nausea, and Vomiting. Reactions like Pain and Induration at the injection site are also common.
  • Uncommon: Generally less frequent reactions include Pruritus (itching), Rash, and Urticaria (hives).

Adverse effects are also categorized by the affected System-Organ Class, including Blood and Lymphatic System Disorders (e.g., transient changes in blood cell counts) and Hepatobiliary Disorders (e.g., Jaundice).


Serious Adverse Reactions and Safety Constraints

The official labeling identifies several serious adverse reactions. The most clinically significant is the risk of Pseudomembranous Colitis or Clostridioides difficile-associated diarrhea (CDAD), which can occur during treatment or up to two months after cessation of therapy. Other serious reactions documented include severe Hypersensitivity Reactions (such as Anaphylaxis) and serious Blood Dyscrasias (e.g., Agranulocytosis).

Specific Safety Constraints are noted for patients with pre-existing conditions. Caution is required in individuals with a history of colitis or gastrointestinal disease, and dose modification requirements are noted for patients with severe hepatic or renal impairment. The medicine is contraindicated in individuals with a known history of hypersensitivity to lincomycin or the related antibiotic clindamycin.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that an overdose of Lincocine (Lincomycin) is expected to present with pronounced gastrointestinal symptoms, including abdominal pain, nausea, vomiting, and diarrhea. The potential for neuromuscular blockade is also recognized in overexposure scenarios.


Manifestations & Severity Emergency Actions & Management
Severe Outcomes include cardio-respiratory arrest and hypotension, especially if the drug is administered intravenously at an excessive concentration or rate. The risk of fatal colitis is also documented as a severe complication. No specific antidote is known for Lincomycin. Treatment is mandated to be symptomatic and supportive, with simple gastric lavage suggested for oral overdose.
Population Risk: The drug's half-life is prolonged in patients with severe renal or hepatic impairment, increasing the risk of accumulation. The injectable solution’s preservative carries a risk of "gasping syndrome" in pediatric patients. Immediate regulatory instructions mandate contacting a regional Poison Centre for suspected overdosage. Immediate medical attention is required for any life-threatening symptoms. Hemodialysis or peritoneal dialysis is not effective for drug removal.

Therapeutic Uses of Lincocine

What Lincocine Treats: Main Uses and Benefits

Treatment of Serious Deep-Seated Infections

Lincocine is commonly used in conditions presenting with systemic or localized discomfort caused by serious, established bacterial infections affecting structures like the musculoskeletal system (e.g., bone and joint infections) and severe skin and soft tissue infections. The treatment helps resolve symptoms that create noticeable physiological strain, such as intense localized pain, and may assist with supporting functional stability.

Systemic Control in Acute Conditions

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as septicaemia (systemic infection) and severe lower respiratory infections (pneumonia). It is applied during phases when symptoms become more noticeable, including high, persistent fever and chills. The treatment contributes to easing the overall symptom load for the patient and supports the patient during these difficult episodes.

Essential Alternative for Allergic Patients

Lincocine is considered a vital alternative treatment for serious infections caused by susceptible organisms in patients with a known allergy to penicillin-class antibiotics. This treatment is applied when appropriate to help manage serious symptoms for individuals with therapeutic constraints, assisting with maintaining a sense of stability during difficult episodes.


Quick Fact: Symptom Focus: Systemic and Localized Discomfort


Eligibility and Restrictions for Use

Who Can and Cannot Use Lincocine?

Eligibility for Lincocine (Lincomycin) is strictly defined by regulatory authorities and is based on a combination of known contraindications, patient age, and existing physiological conditions.

Absolute Contraindications

Lincocine is contraindicated in patients with a known hypersensitivity to lincomycin or clindamycin, which is a related lincosamide antibiotic . It must also not be used for nonbacterial infections, as its action is specific to susceptible bacterial strains.

Population Restrictions and Conditional Use

Population Group Regulatory Status Condition/Restriction
Infants Not Established/Not Recommended Safety and effectiveness have not been established in children younger than 1 month of age .
Organ Impairment Use with Caution Patients with severe renal or hepatic impairment may have a prolonged drug half-life and require careful monitoring.
Gastrointestinal History Use with Caution Caution is advised for individuals with a history of colitis or other serious gastrointestinal disease.
Pregnancy/Lactation Restricted Should only be used if strictly necessary during pregnancy or lactation, as the drug is known to cross the placenta and pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Officially documented interaction patterns for Lincocine involve restrictions based on pharmacodynamic effects, administration rules, and modifications to drug exposure.

Pharmacodynamic Interactions and Restrictions Co-administration with Erythromycin and chemically related macrolide antibiotics should not be concurrent. This is due to demonstrated antagonism in laboratory studies (in vitro), which is noted as having possible clinical significance. The drug’s inherent neuromuscular blocking properties may also enhance the action of other Neuromuscular Blocking Agents (NMBAs). Furthermore, Lincocine may exert a pharmacodynamic antagonistic effect that decreases the therapeutic efficacy of certain live-attenuated vaccines.

Physical and Administration Constraints Lincocine is physically incompatible with the antibiotics Novobiocin and Kanamycin. Regulatory documents state that these substances must not be combined in the same solution for injection.

Exposure Modification A prolonged serum half-life and consequently increased systemic drug exposure is officially noted in patients with severe renal impairment or abnormal hepatic function. This alteration of clearance is a population-specific interaction consideration documented in official prescribing information.

Other Agents Lincocine may decrease the therapeutic efficacy of the combined product Sodium Picosulfate / Magnesium Oxide / Citric Acid and the supplement Ascorbic Acid (Vitamin C).

Mechanism of Action

Targeted Inhibition of Bacterial Protein Synthesis

The mechanism of Lincocine involves its active ingredient, Lincomycin, binding specifically to the 23S ribosomal RNA (rRNA) component of the bacterial 50S ribosomal subunit. This molecular action targets the Peptidyl Transferase Center (PTC) and physically blocks the ribosomal exit tunnel, effectively arresting the elongation of the nascent polypeptide chain. This targeted interference stops the bacteria from manufacturing the essential structural proteins and enzymes needed for growth and replication.

Causal Chain to Pathogen Growth Arrest

By halting the fundamental process of protein creation, Lincomycin induces a state of bacteriostasis, meaning the drug causes the cessation of pathogen proliferation. This results in the modulation of the local bacterial load by preventing further population expansion. This provides the necessary biological condition for host defense mechanisms to clear the existing, non-replicating bacteria, leading to a functional adjustment in the system's biological response.

Structural Basis of Mechanistic Limitations

The drug's effectiveness is constrained by bacterial adaptive responses. The most common limitation involves methylation of 23S rRNA, which reduces Lincomycin's binding affinity to the target site. Additionally, some bacteria utilize efflux pumps to actively remove the drug from their cytoplasm, nullifying the molecular action by preventing the drug from reaching an effective inhibitory concentration.

Dosage and Administration Information

How to Use Lincocine

Lincocine, which contains the active ingredient Lincomycin, is administered under strict conditions. The medicine is classified as a sterile solution and is designed exclusively for parenteral administration.


Official Routes and Administration Principles

Administration is generally accomplished through either Intramuscular (IM) injection or Intravenous (IV) infusion. The required dosage is determined based on the severity of the infection and the patient's specific physiological status. For adults, typical dosing ranges for serious infections involve 600 mg given every 12 to 24 hours by IM route, or 600 mg to 1 g administered every 8 to 12 hours via IV infusion.


Preparation and Procedural Rules

Intravenous infusion requires mandatory dilution before administration. The dose must be diluted in a minimum of 100 mL of a compatible fluid, such as 0.9% Sodium Chloride, ensuring the final concentration does not exceed 10 mg/mL.

Administration is time-controlled: the infusion rate must be slow, not exceeding 1 gram per hour. Consequently, each gram of Lincocine must be infused over a period of at least 60 minutes. The medicine must not be administered undiluted as a rapid injection.


Population-Specific Use

Dosage adjustment is required for specific patient groups. For individuals diagnosed with severe renal or hepatic impairment, the dose must be significantly reduced to approximately 25% to 30% of the amount typically recommended for patients with normal organ function. For pediatric patients over one month of age, dosing is calculated based on body weight, typically in the range of 10 to 20 mg/kg/day in divided doses, depending on the chosen route.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Treatment Efficacy

Research has examined whether this treatment may be associated with changes in the quality of life for individuals with severe refractory seizures.

A large randomized controlled trial (RCT) evaluated whether this medication was associated with a shorter time to symptom improvement compared to the standard-of-care control group. The trial explored the outcome measures of time to symptom resolution and patient-reported quality of life metrics over a 12-week period.

Studies have explored the potential association between the combination therapy and changes in seizure frequency. Research also examined the rates of adverse events reported in the combination therapy group compared to monotherapy groups. Findings were reported over a six-month observation period.

Research into Drug Action and Absorption

Studies have investigated the effects of the treatment on calcium channel activity. Research has investigated whether this activity is associated with changes in the transmission of pain signals. Pre-clinical research examined the substance's effect on nerve depolarization in isolated tissue samples.

Research evaluated the pharmacokinetics of the medication under various administration conditions. Studies evaluated whether co-administration affected the maximum plasma concentration (C max) and the area under the curve (AUC).

Safety and Tolerability Profiles

Research has investigated the tolerability of this treatment in elderly patient populations. Studies focused on documenting common adverse events and serious adverse events (SAEs) across various age groups.

Studies have examined the effects of high doses in individuals with kidney impairment. The research evaluated the elimination half-life (t1/2) and systemic clearance in participants with varying degrees of renal function.

Frequently Asked Questions (FAQ)

Common questions about Lincocine (FAQ)


Q: Can Lincocine be taken with pain medications like ibuprofen?

Official information does not specifically list an interaction with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, regulatory documents describe Lincocine as having properties that may increase the action of other Neuromuscular Blocking Agents (NMBAs). The decision to use this medicine with any other product is determined by a healthcare professional.


Q: Does Lincocine interact with multivitamins?

Regulatory information indicates that Lincocine may decrease the therapeutic efficacy of certain components, specifically Ascorbic Acid (Vitamin C). The effect of other vitamins or minerals found in a standard multivitamin is not specifically addressed in the official product documents.


Q: Is Lincocine the same type of medicine as penicillin?

No, Lincocine is classified as a lincosamide-class antibiotic, while penicillin belongs to the beta-lactam class of antibiotics. The drug is often used for patients who cannot use penicillin due to specific allergies or bacterial resistance patterns. This difference in classification means they operate using distinct mechanisms.


Q: Can Lincocine be used for general inflammation?

The general therapeutic purpose of Lincocine is to control and resolve severe bacterial infections. According to official documents, the medicine is not approved or indicated for use in infections that are nonbacterial in nature, such as general inflammation.


Q: Is it normal to feel tired after starting Lincocine?

Regulatory safety documents list dizziness, somnolence (sleepiness), and fatigue as possible adverse reactions associated with the use of the medicine. If you experience these effects, they are considered reported reactions. Concerns about side effects are typically addressed by a healthcare professional.


Q: Are there any long-term effects associated with Lincocine use?

For prolonged treatments, particularly in children, official safety information recommends the regular monitoring of blood counts and liver function. This monitoring is implemented by a healthcare professional during an extended period of use.


Q: What should I know about Lincocine and alcohol consumption?

While specific, absolute contraindications with alcohol are generally not listed for this drug, official drug information suggests that the use of alcohol or tobacco with certain medicines may cause interactions. The patient's use of alcohol is typically addressed during the consultation with a healthcare professional.


Q: Are there any foods or supplements that interact with Lincocine?

Lincocine is noted to potentially decrease the efficacy of the supplement Ascorbic Acid (Vitamin C). However, general food-timing interactions or restrictions related to meals are not specifically documented in the regulatory source texts for this medicine.


Q: Can Lincocine affect birth control pills?

Some antibiotics, including those in the class of lincomycin, may reduce the effects of hormonal contraception, such as products containing ethinyl estradiol. Any changes to a patient's contraception plan are determined by their prescribing professional.


Q: Is it safe to take Lincocine if I have kidney problems?

Patients with severe renal (kidney) impairment should use Lincocine with caution. This is because the drug's clearance from the body may be slowed, leading to a prolonged drug half-life. Official prescribing information requires a dosage adjustment in such cases.


Q: Can children or teenagers use Lincocine?

Dosing for pediatric patients over one month of age is calculated based on body weight for treatment. However, safety and effectiveness have not been established in children younger than 1 month of age, restricting its use in infants.


Q: Is Lincocine safe for older adults?

Research has investigated the tolerability of the treatment in elderly patient populations. Regulatory information notes that older adults may experience a higher risk of serious adverse reactions, specifically severe diarrhea or Pseudomembranous Colitis. Monitoring is typically implemented by a healthcare professional for this population.


Q: Is Lincocine an opiate or a pain reliever?

Lincocine is classified solely as an antibiotic agent belonging to the lincosamide class. Its primary role is to treat severe bacterial infections by stopping bacterial protein synthesis; it is not classified as an opiate or a general pain reliever.


Q: Why is Lincocine sometimes used instead of other similar drugs?

Lincocine is typically used to treat serious bacterial infections when other drugs, such as penicillins or macrolide antibiotics, may not be suitable. This choice is often due to specific bacterial susceptibilities, patient allergies to other drug classes, or resistance patterns observed in the infection.


Q: Does Lincocine affect blood pressure?

Regulatory documents list hypotension (low blood pressure) under Vascular Disorders as a reported adverse reaction. This effect is sometimes associated with the intravenous administration of the medicine.


Q: Is Lincocine known by any other brand names?

Yes, the active ingredient in Lincocine is Lincomycin. Other brand names that have contained this ingredient include Lincocin, Bactramycin, Lincorex, and L-Mycin.


Q: Can Lincocine be crushed or opened?

Lincocine is formulated as a sterile solution intended exclusively for parenteral administration (injection into a muscle or vein). The currently available form is not designed to be crushed, opened, or administered orally.


Q: Is Lincocine commonly used in hospital settings?

Lincocine is prepared as a sterile solution for parenteral administration (IM or IV injection). This route of administration, which provides immediate, systemic drug delivery, is typical for medicines used in acute or inpatient hospital environments.


Q: Does Lincocine have a risk of dependency or abuse?

Lincocine is an antibiotic and is not classified as a controlled medication by US regulatory agencies. Therefore, it does not carry a formal risk of dependency or abuse as defined for controlled substances.


Q: Are there different forms of Lincocine available (e.g., tablet, liquid)?

The currently available preparation of Lincocine is a sterile solution for injection. While an oral capsule form of the active ingredient existed previously, official sources indicate that the capsule preparation has since been discontinued.


Q: Is Lincocine available over the counter in some countries?

Lincocine contains an ingredient classified as a medically important antibiotic. Official regulations in countries like the US require a prescription for the human-use product. Furthermore, regulations for the veterinary product are transitioning toward requiring professional oversight.

How should Lincocine be stored and disposed of?

Official Storage Requirements

Lincocine (Lincomycin injection) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), to maintain product stability. It is officially mandated to store the solution protected from light and to never allow the material to freeze. The medicine must remain in its original container, and the container should be kept tightly closed until its use. For multi-dose vials, aseptic technique is required to maintain sterility upon withdrawal.

Handling and Disposal

According to regulatory labeling, the product must be stored out of the sight and reach of children. Regarding stability, diluted solutions are typically compatible for 24 hours at room temperature. For disposal of unused or expired product, the contents and container must be discarded in accordance with all local and national regulations. It is strictly prohibited to discharge the product into drains, sewers, or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lincocine found in:

A-Z Index: